top of page
Home
All News
Pharma
APAC
Brazil
Canada Pharma
China Pharma
Europe Pharma
India Pharma
Japan Pharma
North America
Saudi Arabia
US FDA Approvals
Therapy News
Immunology
Neurology
Oncology
Kidney Diseases
Cardiovascular
Infections_Vaccines
Metabolic Diseases
Women Health
Healthcare News
US Healthcare News
US Payer News
Europe Healthcare News
Germany Healthcare
Italy
United Kingdom Healthcare
APAC - Healthcare News
Brazil Healthcare
Healthcare Policies
Conferences
About
All Posts
Healthcare Systems
News
Conferences
Know your disease
COVID
Japan drug approvals
USA Pharma News | Healthcare News
Europe Pharma News
Australia Pharma & Healthcare News
Canada Pharma and Healthcare News
Asia | Pharma | Healthcare News
Indication News
Latam
US FDA News
CMS News
India Drug Healthcare
China Drug Approvals
Europe Healthcare News
US_PayerNews
Radioligand therapy
NICE recommendations
Germany Healthcare Pharma News
HAS Assessment Outcomes
Neurology
Immunology
Blood Disorders
Oncology
Kidney Diseases
Cardiovascular Diseases
Infectious_Vaccines
Search
Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter
Badari Andukuri
Aug 5
FDA Approves Jideytro for Previously Treated ROS1 Positive Non Small Cell Lung Cancer
Badari Andukuri
Jul 22
Aetna Survey Highlights Evolving Payer-Provider Confidence Landscape | iPharmaCenter
Badari Andukuri
Jul 15
FDA Approves KEYTRUDA-Padcev Combo as First Perioperative Standard for Muscle-Invasive Bladder Cancer
Badari Andukuri
Jul 11
Medicare GLP‑1 Bridge Program: Eligibility, Costs, and Drug Details | iPharmaCenter
Badari Andukuri
Jun 25
FDA Clears Sanofi’s Tzield as First Disease-Modifying Therapy for Stage 3 Type 1 Diabetes | iPharmaCenter
Badari Andukuri
Jun 17
Baxfendy (baxdrostat) Approved in the US as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension | iPharmaCenter
Badari Andukuri
May 18
Foundayo (orforglipron) Wins FDA Approval as First Anytime GLP‑1 Tablet for Weight Loss | iPharmaCenter
Badari Andukuri
Apr 8
Johnson and Johnson approved Tecvayli plus Darzalex Faspro for 2L multiple myeloma | iPharmaCenter
Badari Andukuri
Mar 7
FDA says no to AstraZeneca’s Saphnelo Subcutaneous Formulation for Lupus Patients | iPharmaCenter
Badari Andukuri
Feb 7
AHA Urges HRSA to Block Eli Lilly’s Expanded 340B Claims-Data Policy; Lilly Hits Back | iPharmaCenter
Badari Andukuri
Jan 31
Amlitelimab meets primary endpoints in Phase 3 atopic dermatitis trials, enabling Sanofi regulatory submissions | iPharmaCenter
Badari Andukuri
Jan 26
FDA clears one‑minute subcutaneous mosunetuzumab for heavily pretreated follicular lymphoma | iPharmaCenter
Badari Andukuri
Jan 23
Lilly’s Sofetabart Mipitecan Wins FDA Breakthrough Tag in Tough‑to‑Treat Ovarian Cancer | iPharmaCenter
ipharmaservices
Jan 22
Sun Pharma Launches UNLOXCYT in the U.S. for Advanced Cutaneous Squamous Cell Carcinoma
ipharmaservices
Jan 17
Boehringer Ingelheim Bolsters Pulmonary Fibrosis Portfolio with Jascayd Approval for Progressive Cases
Badari Andukuri
Dec 23, 2025
FDA Clears Wegovy Pill as First Oral GLP-1 for US Weight Management
ipharmaservices
Dec 23, 2025
FDA Clears Breyanzi as the First CAR T‑Cell Therapy for Relapsed or Refractory Marginal Zone Lymphoma in the US | iPharmaCenter
Badari Andukuri
Dec 5, 2025
US FDA Accepts AstraZeneca’s Baxdrostat for Priority Review in Resistant Hypertension
ipharmaservices
Dec 4, 2025
FDA Approves Jaypirca for Relapsed or Refractory CLL/SLL Previously Treated with Covalent BTK Inhibitors | iPharmaCenter
ipharmaservices
Dec 4, 2025
bottom of page
